EGFR and non-small cell lung carcinoma: Randomized clinical trials conducted in non-small-cell lung cancer (NSCLC) carrying activating mutations of the epidermal growth factor receptor (EGFR) have clearly shown that tyrosine kinase inhibitors (TKIs) dramatically contribute to improve prognosis, disease control, symptoms and quality of life when compared to traditional platinum-based chemotherapy [1-5].